Indications to LDLT: a changing pathway?
AbstractLiver transplantation (LT) revolutionized the outlook for cirrhotic patients, offering a potential cure with over 80% life expectancy after 5 years. Cirrhosis, with or without hepatocellular carcinoma (HCC), is the primary LT indication. Living donor LT (LDLT) initially explored as an alternative, declined due to poorer outcomes. Studies on LDLT improved outcomes through precise recipient selection, emphasizing the importance of careful donor/recipient matching. Emerging concepts like left lobe preference and minimally invasive donor approaches enhance LDLT outcomes. The RAPID technique shows promise in both cirr...
Source: Updates in Surgery - April 9, 2024 Category: Surgery Source Type: research
Immunogenicity of COVID-19 vaccines in patients with cirrhosis: Expected advantage for additional dose of vaccine
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - April 9, 2024 Category: Allergy & Immunology Authors: Hinpetch DaungsupawongViroj Wiwanitkita Private Academic Consultant, Phonhong, Lao People ’s Democratic Republicb Medical College, Saveetha Institute of Medical and Technical Sciences Saveetha University India, Chennai, India Source Type: research
Phenotypes of MASLD-associated hepatocellular carcinoma
Hepatocellular carcinoma (HCC) typically develops as consequence of liver cirrhosis, but HCC epidemiology has evolved drastically in recent years. Metabolic dysfunction-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis (MASH), has emerged as the most common chronic liver disease worldwide and a leading cause of HCC. A substantial proportion of MASLD-associated HCC (MASLD-HCC) can also develop in patients without cirrhosis. The specific pathways that trigger carcinogenesis in this context are not completely elucidated, and recommendations for HCC surveillance in MASLD pat...
Source: Clinical Gastroenterology and Hepatology - April 9, 2024 Category: Gastroenterology Authors: Jes ús Rivera-Esteban, Sergio Muñoz-Martínez, Mónica Higuera, Elena Sena, María Bermúdez-Ramos, Juan Bañares, María Martínez-Gomez, M Serra Cusidó, Alba Jiménez-Masip, Sven M. Francque, Frank Tacke, Beatriz Minguez, Juan M. Pericàs. Tags: Narrative Reviews Source Type: research
Clinical characteristics of choledochal cysts with intrahepatic bile duct dilatations: an observational study
CONCLUSION: Most IHBDs can recover to normal postoperatively in a short time, and proactive treatment is recommended for CC patients with IHBD dilatation for significant abnormal liver functions.PMID:38586557 | PMC:PMC10995834 | DOI:10.4174/astr.2024.106.4.225 (Source: Annals of Surgical Treatment and Research)
Source: Annals of Surgical Treatment and Research - April 8, 2024 Category: Surgery Authors: Ken Chen Shuhao Zhang Duote Cai Yuebin Zhang Yi Jin Wenjuan Luo Zongwei Huang Di Hu Zhigang Gao Source Type: research
Spectrally separated dual-label upconversion luminescence lateral flow assay for cancer-specific STn-glycosylation in CA125 and CA15-3
Anal Bioanal Chem. 2024 Apr 8. doi: 10.1007/s00216-024-05275-z. Online ahead of print.ABSTRACTMultiplexed lateral flow assays (LFAs) offer efficient on-site testing by simultaneously detecting multiple biomarkers from a single sample, reducing costs. In cancer diagnostics, where biomarkers can lack specificity, multiparameter detection provides more information at the point-of-care. Our research focuses on epithelial ovarian cancer (EOC), where STn-glycosylated forms of CA125 and CA15-3 antigens can better discriminate cancer from benign conditions. We have developed a dual-label LFA that detects both CA125-STn and CA15-3-...
Source: Cancer Control - April 7, 2024 Category: Cancer & Oncology Authors: Miikka Ekman Teppo Salminen Kirsti Raiko Tero Soukka Kamlesh Gidwani Iida Martiskainen Source Type: research
Analysis of clinical characteristics of persistent HBeAg positivity in patients with chronic hepatitis B treated with nucleos(t)ide analogues
Conclusion: HBeAg-positive patients with chronic hepatitis B have persistent HBeAg positivity when treated with long-term nucleos(t)ide analogues. Accordingly, a greater proportion of this kind of patient family and mothers have a remarkable history of hepatitis B and a reduced HBV DNA relapse rate in the early stages (within a year or less).PMID:38584099 | DOI:10.3760/cma.j.cn501113-20230822-00065 (Source: Cancer Control)
Source: Cancer Control - April 7, 2024 Category: Cancer & Oncology Authors: L P Peng W Q Gan Y B Zheng Y M Chen J Liu Z B Wu Z L Gao Source Type: research
Spectrally separated dual-label upconversion luminescence lateral flow assay for cancer-specific STn-glycosylation in CA125 and CA15-3
Anal Bioanal Chem. 2024 Apr 8. doi: 10.1007/s00216-024-05275-z. Online ahead of print.ABSTRACTMultiplexed lateral flow assays (LFAs) offer efficient on-site testing by simultaneously detecting multiple biomarkers from a single sample, reducing costs. In cancer diagnostics, where biomarkers can lack specificity, multiparameter detection provides more information at the point-of-care. Our research focuses on epithelial ovarian cancer (EOC), where STn-glycosylated forms of CA125 and CA15-3 antigens can better discriminate cancer from benign conditions. We have developed a dual-label LFA that detects both CA125-STn and CA15-3-...
Source: Analytical and Bioanalytical Chemistry - April 7, 2024 Category: Chemistry Authors: Miikka Ekman Teppo Salminen Kirsti Raiko Tero Soukka Kamlesh Gidwani Iida Martiskainen Source Type: research
